Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06450899 · ClinicalTrials.gov registry record · Phase 2

Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

A Phase 2 study, sponsored by University of Colorado, Denver.

Completed
Registry status
Phase 2
Development phase
57
Enrollment target

NCT06450899 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 57 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06450899, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.

COMPLETED
Registry status
Phase 2
Development phase
57 participants
Enrollment target

Study Summary

This study is a trial looking at a drug to help prevent acute mountain sickness. The drug is prochlorperazine, a drug commonly used to treat nausea vomiting and headache. Participants will either take the drug or a placebo, and hike to and sleep at the summit of Mount Blue Sky located at 4,348 meters (14,265 feet).

Interventions

  • DRUG Placebo
  • DRUG Prochlorperazine Maleate

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2024-08-05
Est. Completion 2024-08-28
Phase Phase 2

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT06450899

The ClinicalTrials.gov registry entry for NCT06450899 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06450899 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06450899 about?

NCT06450899 is a clinical study titled "Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness". This study is a trial looking at a drug to help prevent acute mountain sickness. The drug is prochlorperazine, a drug commonly used to treat nausea vomiting and headache. Participants will either take the drug or a placebo, and hike to and sleep at the summit of Mount Blue Sky located at 4,348 meter...

What is the current status of trial NCT06450899?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2024-08-05. Estimated completion is 2024-08-28.

What interventions are being tested in trial NCT06450899?

The interventions under investigation include: Placebo (DRUG), Prochlorperazine Maleate (DRUG).

Who is sponsoring clinical trial NCT06450899?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.